anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a substitute plasma agent which improves the pH stability of a conventional substitute plasma agent using 200,000 HES (hydroxyethylstarch having a weight-average mol. wt. of 200,000) after thermally sterilized, and have no significant decrease in pH, even when thermally sterilized at a temperature of ≥110°C for ≥10 min and further even when charged in a plastic bag having high oxygen permeability and then thermally sterilized.  <P>SOLUTION: This substitute plasma agent containing hydroxyethylstarch having a weight-average mol. wt. of 150,000 to 300,000 and only sodium ion and chloride ion as electrolytes is characterized by further containing citrate ion as a pH-adjusting agent.  <P>COPYRIGHT: (C)2004,JPO
This research is being done because people with diabetes have reduced healing capacity. This can be problematic because wounds that do not heal may turn into ulcers which may lead to more severe complications. Non-weight bearing exercise has many positive health benefits that improve metabolic and vascular health which will then improve healing time. Therefore, the purpose of this study is to evaluate the positive effects of non-weight bearing exercise. Once the effects of non-weight bearing exercise are confirmed, progress towards the prevention and treatment of diabetic foot ulcers and complications may be possible. Potential participants are eligible for the study if diagnosed with type 2 diabetes and have a foot ulcer or wound. Approximately 40 subjects with Type 2 Diabetes are expected to complete this study. Participation in this study requires medical clearance following a screening visit and then being randomly assigned to a non-weight bearing exercise training group or a control group. Both groups will receive standard diabetic and wound care. Subjects will complete 7 study visits at the University of Michigan. The research tests during these visits will include measures of body composition, oral glucose tolerance test, exercise testing, blood draws, vascular function measurements, wound measurement, single-leg exercise session and group randomization If randomized to the Exercise Group subjects will be asked to visit the University of Michigan three days a week for 6 weeks. During each visit during this 6-week period, subjects will perform exercise training by completing 30 minutes of single-leg exercise at approximately 50% of a predetermined maximal effort. Regardless of the group subjects are randomized to, all will receive standard care for the management of diabetes foot ulcer/wound.
The current study will examine the efficacy of a virtual reality (VR) intervention entitled "IMPRoving Expression of Skills and Strengths In Interviewing in a Virtual Environment" (IMPRESSIVE) which targets social competency skills needed for successful job interviewing. Specifically, 2 VR tools are utilized in the IMPRESSIVE intervention. The first tool is VR-Job Interview Training, a VR program which offers the opportunity for repeated practice with a virtual human interviewer. Preliminary evidence suggests that the VRprogram is successful in adults with ASD and schizophrenia in improving interview abilities. However, the efficacy of it has not been evaluated in adolescents with ASD. This represents a significant void in our knowledge, as we do not know whether this program is effective for youth. In addition to VR training, a newly developed tool is included in the currently proposed intervention: the Kessler Foundation STRength IDentification and Expression tool (VR-STRIDE). KF-STRIDE is focused on improving the ability to express personal strengths during the job interview, a skill that is not taught with VR training. The proposed IMPRESSIVE intervention, which combines the learning of 2 critical abilities (social skills and strength identification), has never been examined in individuals with ASD. Thus, the current proposal will be the first to examine the efficacy of these 2 combined tools in this at-risk population.
CXCL3 (C-X-C Motif Chemokine 3), a member of the C-X-C chemokine subfamily, operates as a potent chemoattractant for neutrophils, thereby orchestrating the recruitment and migration of leukocytes alongside eliciting an inflammatory response. Recent inquiries have shed light on the pivotal roles of CXCL3 in the context of carcinogenesis. In the tumor microenvironment, CXCL3 emanating from both tumor and stromal cells intricately modulates cellular behaviors through autocrine and paracrine actions, primarily via interaction with its receptor CXCR2. Activation of signaling cascades such as ERK/MAPK, AKT, and JAK2/STAT3 underscores CXCL3's propensity to favor tumorigenic processes. However, CXCL3 exhibits dualistic behaviors, as evidenced by its capacity to exert anti-tumor effects under specific conditions. Additionally, the involvement of CXCL3 extends to inflammatory disorders like eclampsia, obesity, and asthma. This review encapsulates the structural attributes, biological functionalities, and molecular underpinnings of CXCL3 across both tumorigenesis and inflammatory diseases.
A control group of subjects from the treatment waiting list who meet the inclusion criteria will be used. An intra-oral scanner will record the baseline occlusal relationship (T0) and will be repeated after six months (T5). The control group will also have a standard pre-treatment lateral cephalogram radiograph taken, as well as conventional and three-dimensional stereophotogrammetry at baseline (T0) and after six months (T5). This will allow changes resulting from growth to be assessed whilst no active orthodontic treatment has taken place.
PURPOSE:To obtain a hair tonic remarkably effective to the dandruff and itchiness, etc., of scalp and hair and useful for the prevention and remedy of alopecia, by using a fermentation product of Neurospora sitophila as an active component. CONSTITUTION:A fermentation product is produced by culturing Neurospora sitophila in a medium containing peanut and/or soybean. The fermentation product is used as it is or in the form of a squeezed juice or extracted liquid to obtain a hair tonic. The fermentation liquid or its extracted liquid can be used singly as it is or as a compounding raw material for hair tonic to form a lotion, hair oil, hair liquid, hair cream, shampoo, rinse, etc. The fermentation product contains various amino acids, peptides, sugars, organic acids, vitamins, inorganic salts, etc., and is effective in imparting properties desirable as a hair tonic. Especially, Neurospora sitophila produces a large amount of carotenoid pigment and is extremely effective for the growth of hair.
The present invention shows in vivo myogenic differentiation of muscle progenitor cells (MPCs), being derived from joint tissue, in a mouse model of skeletal muscle regeneration. MPCs participated in the regeneration process by long-term persistence and contribution to the compartment of myonuclei and the pool of functional satellite cells. When injected into dystrophic muscles of immunosuppressed mdx mice, human MPCs restored dystrophin in some fibers, and rescued the expression of mouse mechano-growth factor. In addition, the human MPCs derived from synovial membrane were injected into infarcted myocardial muscle. The MPCs engrafted successfully, underwent proliferation and differentiation leading to functional recovery and maintenance of the cardiac muscle. MPCs represent an alternative source of myogenic cells in therapeutic approaches for postnatal skeletal and cardiac muscle repair.
PCT No. PCT/GB95/01985 Sec. 371 Date Feb. 14, 1997 Sec. 102(e) Date Feb. 14, 1997 PCT Filed Aug. 21, 1995 PCT Pub. No. WO96/05740 PCT Pub. Date Feb. 29, 1996A baby or infant composition is provided which comprises one or more nutrient materials and, as a supplement, nervonic acid or a functional derivative thereof or an immediate biochemical precursor of either nervonic acid or a functional derivative thereof, in a physiologically acceptable form. It has been found to be beneficial to administer such a composition to preterm babies and term babies and infants. It has also been to be beneficial to administer nervonic acid or a functional derivative thereof or an immediate biochemical precursor of either nervonic acid or a functional derivative thereof to adults having normal levels of nervonic acid in their body and, in particular, to women who intend to become pregnant, pregnant women and lactating women.
Patients with spine pathology demonstrate an above average rate of active psychiatric disorders, which can influence their recovery. This study was designed to understand how mental health diagnoses (ie, anxiety and depression) influence a patient's postoperative need for opioids after a single level cervical spine fusion. The PearlDiver database was used to identify patients. Patients were placed into one of four groups: those with a diagnosis of depression, those with a diagnosis of anxiety, those with a diagnosis of both anxiety and depression, and a control group. Chi-square tests were used to assess differences in the number of patients filling initial and additional opioid prescriptions for up to 90 days after their fusion. A total of 168,967 patients who underwent an elective cervical spine fusion in the United States between 2010 and 2021 were included in this study. The control group filled significantly more opioid prescriptions within the first 90 days after their cervical fusion (P<.001). There was no difference among the study groups regarding the need to fill additional opioid prescriptions. Patients with a diagnosis of depression and/or anxiety may present as complex patients; however, results suggest they do not need additional opioids for pain control after a single level cervical spine fusion. [Orthopedics. 2024;47(2):89-94.].
BACKGROUND: Neoadjuvant chemoradiotherapy (NCRT) is recommended as the treatment standard for locally advanced esophageal squamous cell carcinoma (ESCC). The use of immunotherapy in the neoadjuvant setting has gained attention. Multiple, clinical trials have explored the efficacy and safety of neoadjuvant immunochemotherapy (NICT). We evaluated the differences in clinicopathologic outcomes and the patterns of lymphatic spread among patients receiving neoadjuvant chemotherapy (NCT), NCRT, and NICT before esophagectomy for locally advanced ESCC.
METHODS: A total of 702 patients with ESCC who completed transthoracic esophagectomy followed neoadjuvant therapy were included. Pathological characteristics, including pathologic complete response (pCR), tumor regression grade (TRG) score and patterns of lymphatic spread, were evaluated.
RESULTS: Compared with the NCT group, the NCRT group and NICT group had an advantage in pathological response (P < 0.05). The pCR rate was 8.1% in the NCT group, 29.9% in the NCRT group, and 23.6% in the NICT group. The TRG score (P < 0.05) and pathologic T stage (P < 0.05) in the NCT group were significantly higher. Compared with NICT, NCRT can significantly reduce the rate of lymph node metastasis rate in station 1R (0 vs. 3.4%, P < 0.05) and 2R (1.1% vs. 6.8%, P < 0.05). Subgroup analysis according to the tumor location distribution showed that NICT group had higher lymph node metastasis rate in station 2R (9.1%) in middle thoracic cases (P < 0.05) and in station 18 (7.5%) (P < 0.05) in lower thoracic cases.
CONCLUSIONS: NCRT or NICT followed by surgery may result in a promising pCR rate and show a better performance in therapeutic response of primary lesion. For patients with lymph node metastasis in station 1R and 2R, NCRT should be the optimal preoperative treatment strategy.
BACKGROUND: In thoracic esophagectomy, anastomotic leakage is one of the most important surgical complications. Indocyanine green (ICG) is the most widely used method to assess tissue blood flow; however, this technique has been pointed out to have disadvantages such as difficulty in evaluating the degree of congestion, lack of objectivity in evaluating the degree of staining, and bias easily caused by ICG injection, camera distance, and other factors. Evaluating tissue oxygen saturation (StO2) overcomes these disadvantages and can be performed easily and repeatedly. It is also possible to measure objective values including the degree of congestion. We evaluate novel imaging technology to assess tissue oxygen saturation (StO2) in the gastric conduit during thoracic esophagectomy.
METHODS: Fifty patients were enrolled, with seven excluded due to intraoperative findings, leaving 43 for analysis. These patients underwent thoracic esophagectomy for esophageal cancer. The device was used intraoperatively to evaluate tissue oxygen saturation (StO2) and total hemoglobin index (T-HbI), which guided the optimal site for gastric tube anastomosis. The efficacies of StO2 and T-HbI in relation to short-term outcomes were analyzed.
RESULTS: StO2, indicating blood supply to the gastric tube, remained stable beyond the right gastroepiploic artery (RGEA) end but significantly decreased distally to the demarcation line (p <  0.05). T-HbI, indicative of congestion, significantly decreased past the RGEA (p <  0.05). Three patients experienced anastomotic leakage. These patients exhibited significantly lower StO2 (p <  0.01) and higher T-HbI (p <  0.01) at both the RGEA end and the demarcation line. Furthermore, the anastomotic site, usually within 3 cm of the RGEA's anorectal side, also showed significantly lower StO2 (p <  0.01) and higher T-HbI (p <  0.01) in patients with anastomotic leakage.
CONCLUSIONS: The novel device provides real-time, objective evaluations of blood flow and congestion in the gastric tube. It proves useful for safer reconstruction during thoracic esophagectomy, particularly by identifying optimal anastomosis sites and predicting potential anastomotic leakage.
Mitochondria play an important role in pressure overload-induced cardiac hypertrophy. The present study aimed to investigate the role of mitochondrial transient receptor potential vanilloid 3 (TRPV3) in myocardial hypertrophy. A 0.7 mm diameter U-shaped silver clip was used to clamp the abdominal aorta of Sprague Dawley (SD) rats and establish an animal model of abdominal aortic constriction (AAC). Rat H9C2 myocardial cells were treated with angiotensin II (Ang II) to establish a hypertrophic myocardial cell model, and TRPV3 expression was knocked down using TRPV3 small interfering RNA (siRNA). JC-1 probe was used to detect mitochondrial membrane potential (MMP). DHE probe was used to detect ROS generation. Enzyme activities of mitochondrial respiratory chain complex I and III and ATP production were detected by assay kits. Immunofluorescence staining was used to detect TRPV3 expression in H9C2 cells. Western blot was used to detect the protein expression levels of β-myosin heavy chain (β-MHC), mitochondrial TRPV3 and mitochondrial NOX4. The results showed that, in the rat AAC model heart tissue and H9C2 cells treated with Ang II, the protein expression levels of β-MHC, mitochondrial TRPV3 and mitochondrial NOX4 were up-regulated, MMP was decreased, ROS generation was increased, mitochondrial respiratory chain complex I and III enzyme activities were decreased, and ATP production was reduced. After knocking down mitochondrial TRPV3 in H9C2 cells, the protein expression levels of β-MHC and mitochondrial NOX4 were down-regulated, MMP was increased, ROS generation was decreased, mitochondrial respiratory chain complex I and III enzyme activities were increased, and ATP production was increased. These results suggest that mitochondrial TRPV3 in cardiomyocytes exacerbates mitochondrial dysfunction by up-regulating NOX4, thereby participating in the process of pressure overload-induced myocardial hypertrophy.
Chromatin configuration serves as a principal indicator of GV (germinal vesicle)-stage oocyte quality. However, the underlying mechanisms governing the chromatin configuration transition from NSN (non-surrounded nucleolus) to SN (surrounded nucleolus) remain unclear. In this study, by conducting a quantitative proteomic analysis, we identified an increased expression of the MIB2 (MIB E3 ubiquitin protein ligase 2) protein in SN oocytes. Specific depletion of MIB2 in SN oocytes not only leads to severe disruption of the meiotic apparatus and a higher incidence of aneuploidy but also adversely affects meiotic maturation and early embryo development. Notably, overexpression of MIB2 in NSN oocytes facilitates the chromatin configuration transition. Meantime, we observed that forced expression of MIB2 in NSN oocytes significantly mitigates spindle/chromosome disorganization and aneuploidy. In summary, our results suggest that chromatin configuration transition regulated by MIB2 is crucial for oocytes to acquire developmental competence.
PURPOSE:To immobilize an immunonogically active material such as antigen or antibody or physiologically active material such as hapten or drug to liposome by preliminarily incorporating an amphiphilic compd. into the liposome. CONSTITUTION:The amphiphilic compd. of about 50,000-30,000mol.wt. is preliminarily incorporated into the liposome at the time of preparing the liposome and the immunonogically active material, physiologically active material, etc., are bonded to the liposome via said compd. These materials are then immobilized in the position adequately apart from the liposome surface and, therefore, the damaging of the film surface of the liposome by the immobilization is prevented. In addition, the stable and efficient immobilization is exedutable. Polysaccharides such as lipopolysaccharide and natural polypeptide having a hydrophobic property, etc., are used as the amphiphilic compd.
Fenofibrate is a lipid regulating agent available as tablets for oral administration. Each tablet contains 54 mg or 160 mg of fenofibrate, USP. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following structural formula: 

The molecular formula is C20H21O4Cl and the molecular weight is 360.83; fenofibrate is insoluble in water. The melting point is 79-82°C. Fenofibrate, USP is a white solid which is stable under ordinary conditions. 

Inactive Ingredients: Each tablet contains betadex, colloidal silicon dioxide, dibasic calcium phosphate dihydrate, docusate sodium with sodium benzoate, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate (potato) and titanium dioxide. In addition, the 54 mg individual tablets contain D&C Yellow No. 10 Aluminum Lake and FD&C Yellow No. 6 Aluminum Lake.

Meets USP Dissolution Test 3.
PURPOSE OF REVIEW: To review the current management of the axilla in breast cancer.
RECENT FINDINGS: Axillary dissection is no longer indicated in patients with clinically node-negative axilla with 1-2 positive sentinel lymph nodes following upfront surgery or in patients with clinically node-negative axilla following neoadjuvant chemotherapy. Breast cancer has evolved away from routine axillary clearance to the less invasive sentinel lymph node biopsy to now complete omission of axillary sampling in select patients. We will review the most salient evidence that has shaped these practice changes over the last three decades. Current practice controversies are especially relevant for elderly populations and those receiving neoadjuvant therapy. Ongoing clinical trials will provide data to further guide breast cancer surgical management.
Cervical dentin hypersensitivity is a painful condition and is a clinical challenge due to different treatment strategies available. The aim of this study is through a randomized clinical trial, double blind, splith-mouth, evaluate the various types of protocols and clinical efficacy in the reduction or even elimination of dentinal hypersensitivity. A hundred forty teeth of healthy patients of both sexes were selected. Visual Analog Scale was used pain (VAS) to measure the intensity of the patient's pain. The teeth will be randomly divided into 7 different groups according to the desensitization treatment under study: Desensibilize KF - FGM Dental Products, Clinpro - 3M Company, Minnesota - USA, Photon Laser III - DMC, Brazil, Desensibilize KF and laser, Desensibilize KF and Clinpro, laser and Clinpro and the association of all products. Data will be collected, tabulated and submitted to statistical analysis.
Those subjects randomized to the sham procedure arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
<P>PROBLEM TO BE SOLVED: To provide a method for reducing a body weight and to provide a method for treating obesity in humans.  <P>SOLUTION: This method for reducing the body weight and treating obesity comprises a step of administering a nutritionally effective amount of a conjugated linoleic acid to humans. The conjugated linoleic acid in the form of a free acid or its chemical derivative can be fed in a pill or as a component of a prepared food. The method for treating the obesity in humans is also provided. The method comprises a step of orally administering a therapeutically effective amount of the conjugated linoleic acid. The nutritionally effective amount or the therapeutically effective amount of the conjugated linoleic acid is preferably about 0.1 to 15 g per day.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Whole-genome sequencing (WGS) studies of autism spectrum disorder (ASD) have demonstrated the roles of rare promoter de novo variants (DNVs). However, most promoter DNVs in ASD are not located immediately upstream of known ASD genes. In this study analyzing WGS data of 5,044 ASD probands, 4,095 unaffected siblings, and their parents, we show that promoter DNVs within topologically associating domains (TADs) containing ASD genes are significantly and specifically associated with ASD. An analysis considering TADs as functional units identified specific TADs enriched for promoter DNVs in ASD and indicated that common variants in these regions also confer ASD heritability. Experimental validation using human induced pluripotent stem cells (iPSCs) showed that likely deleterious promoter DNVs in ASD can influence multiple genes within the same TAD, resulting in overall dysregulation of ASD-associated genes. These results highlight the importance of TADs and gene-regulatory mechanisms in better understanding the genetic architecture of ASD.
GSK1349572 2 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
FIELD: medicine. SUBSTANCE: claimed invention describes drugs having anxyolytic activity and containing as active ingredient 1-styrylisoquinoline derivatives of general formula (I):wherein n is 1,2,3 or 4; R may have the same or different meanings and is hydrogen, lower alkyl, lower alkoxy or hydroxy or two R substituents connected with adjacent carbon atoms may form in combination with each other, alkylenedioxy group; Ris hydrogen or lower alkyl and Ar is optionally substituted aryl or heteroaryl. There are known in the art some compounds of general formula (I). However most of these compounds have not been described in literature. The claimed invention describes process for preparing novel compounds of general formula (I) which comprises reacting compounds of formula II:, with aldehyde of general formula (III): Ar-CHO in the presence of condensing agent or acid catalyst. EFFECT: improved properties of the drugs.